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Abstract
Background:  Hypermethylation of the TGFBI  promoter has been shown to correlate with
decreased expression of this gene in human tumor cell lines. In this study, we optimized a
methylation-specific polymerase chain reaction (MSP) method and investigated the methylation
status of the TGFBI promoter in human lung and prostate cancer specimens.
Methods: Methylation-specific primers were designed based on the methylation profiles of the
TGFBI promoter in human tumor cell lines, and MSP conditions were optimized for accurate and
efficient amplification. Genomic DNA was isolated from lung tumors and prostatectomy tissues of
prostate cancer patients, bisulfite-converted, and analyzed by MSP.
Results: Among 50 lung cancer samples, 44.0% (22/50) harbored methylated CpG sites in the
TGFBI promoter. An analysis correlating gene methylation status with clinicopathological cancer
features revealed that dense methylation of the TGFBI promoter was associated with a metastatic
phenotype, with 42.9% (6/14) of metastatic lung cancer samples demonstrating dense methylation
vs. only 5.6% (2/36) of primary lung cancer samples (p < 0.05). Similar to these lung cancer results,
82.0% (41/50) of prostate cancer samples harbored methylated CpG sites in the TGFBI promoter,
and dense methylation of the promoter was present in 38.9% (7/18) of prostate cancer samples
with the feature of locoregional invasiveness vs. only 19.4% (6/31) of prostate cancer samples
without locoregional invasiveness (p < 0.05). Furthermore, promoter hypermethylation correlated
with highly reduced expression of the TGFBI gene in human lung and prostate tumor cell lines.
Conclusion: We successfully optimized a MSP method for the precise and efficient screening of
TGFBI promoter methylation status. Dense methylation of the TGFBI promoter correlated with the
extent of TGFBI gene silencing in tumor cell lines and was related to invasiveness of prostate tumors
and metastatic status of lung cancer tumors. Thus, TGFBI promoter methylation can be used as a
potential prognostic marker for invasiveness and metastasis in prostate and lung cancer patients,
respectively.
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Background
Cancers of the lung and prostate contribute to a signifi-
cant fraction of cancer-related deaths in the United States
[1,2]. For lung cancer, approximately 50% of patients
have metastatic disease at the time of diagnosis, which
contributes to a less than 15% overall survival rate [1]. The
poor survival of lung cancer patients is in part attributed
to undetectable tumor micrometastasis at the time of sur-
gery for even relatively early-stage disease, which is
responsible for later relapse with the development of
nodal and/or distant metastasis [3]. Furthermore, there is
no highly effective curative therapy for advanced or hor-
mone-refractory prostate cancer [4]. A better understand-
ing of the molecular mechanisms associated with lung
and prostate cancer progression may aid in the develop-
ment of improved diagnosis, clinical management, and
outcome prediction. In particular, the discovery of epige-
netic biomarkers for cancer invasiveness and metastasis
may help in the identification of patients at risk for more
aggressive cancer disease courses. This would potentially
help clinicians to devise effective intensified and/or novel
therapeutic strategies to prevent or decrease the likelihood
of tumor progression to invasiveness and metastasis in
such high-risk patients.
Hypermethylation of CpG site clusters (CpG islands)
within the promoter region of genes has been character-
ized as a common epigenetic alteration for the silencing or
inactivation of tumor suppressor genes in human malig-
nancies including lung and prostate cancers [5-7]. Due to
their heritable nature, both genetic and epigenetic altera-
tions pose a great risk for cancer development [8]. Aber-
rant methylation of p16INK4a, FHIT, APC, MLH1,
RASSF1, CDKN2A, and DAPK has been associated with
lung cancer stage, metastasis, and an increased risk of
recurrence after therapy [9]. GSTP1, encoding the π-class
glutathione S-transferase (GST) capable of detoxifying
electrophilic and oxidant carcinogens, was the first
reported gene silenced by CpG island hypermethylation
in prostate cancer [10]. Subsequent studies have identified
more than 40 genes that are targeted by DNA hypermeth-
ylation in prostate cancer cells, including RASSF1A (ras
association domain family protein 1, isoform A), RARβ2
(retinoic acid receptor β2), p16INK4a, and PTEN (phos-
phatase and tensin homolog) tumor suppressor genes
[11-13]. Although silencing of other tumor suppressor
genes, such as RB1 (retinoblastoma-1 gene), MLH-1 (mis-
match repair gene), and VHL (von Hippel-Lindau gene),
through DNA hypermethylation is relatively rare in pros-
tate cancer, it is common in other types of malignancies
[5].
TGFBI, also known as Betaig-h3, is a secreted protein
induced by transforming growth factor-β (TGF-β) in
human adenocarcinoma cells as well as in other human
cell types [14], and has been shown to possess tumor sup-
pressor function in in vitro studies [15]. An earlier study
from our laboratory demonstrated a dense methylation
pattern of the TGFBI promoter in human tumor cell lines,
including both lung (H522, H810, H1417) and prostate
(DU145) tumor cell lines, with a complete loss or low
level of TGFBI expression in these cell lines. In contrast,
only sparsely methylated or unmethylated CpG sites were
identified in cell lines with a rich level of TGFBI expres-
sion, including normal, immortalized, and several tumor
cell lines [16]. In this study, we have examined the pro-
moter methylation of the TGFBI gene in 100 cases of lung
and prostate cancers by using an optimized MSP method.
Our study revealed that dense TGFBI promoter methyla-
tion is correlated with the invasiveness of prostate cancers,
and with the metastatic status of lung cancers. TGFBI
methylation may thus serve as a useful prognostic biomar-
ker, and our optimized MSP method may be useful for
evaluation of TGFBI promoter methylation in a wide vari-
ety of tumor samples.
Methods
Lung and Prostate Cancer Patient Samples
Genomic DNA of lung cancer samples from 50 non-small
cell lung cancer patients – consisting of 36 primary lung
cancer tumor samples, 10 lymph node metastasis sam-
ples, and 4 distant metastasis samples – were purchased
from Oncomatrix (San Marcos, CA). Frozen tissue from
the prostatectomy specimens of 50 prostate adenocarci-
noma patients who had undergone therapeutic prostatec-
tomy was obtained from the Columbia University Tumor
Bank. Fifteen tissue sections of seven-micron thickness
were procured for each patient. A phenol-chloroform pro-
cedure was used to isolate genomic DNA from cancer
specimens. For the prostate portion, we obtained
approval from the Columbia IRB using "exempt status"
(i.e., examination of pathological specimens that contain
no patient identifier information, protocol number IRB X-
10005).
In our analysis, we divided the lung cancer patients into
two groups based on specimen source: patients whose
tumor specimen was derived from the primary lung tumor
site vs. those whose tumor specimen was obtained from a
metastatic site (lymph node or distant). Lung cancer spec-
imen source type was then correlated with TGFBI methyl-
ation status. Likewise, prostate cancer patients were
divided into two groups based on a specific classification
system: patients who did not have pathological features of
locoregional invasiveness (extracapsular extension = stage
pT3a, seminal vesicle involvement = stage pT3b, margin
positivity, and/or regional lymph node involvement =
stage pN1) vs. those who did have one or more such fea-
tures of locoregional invasiveness. We then correlated theBMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
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presence vs. absence of locoregional invasiveness with
TGFBI methylation status.
As a point of clarification, we included pathological pros-
tatectomy margin positivity as a feature that would qualify
a patient's disease as having locoregional invasiveness
present (in addition to pT3 or pN1 disease), which is sup-
ported by previous studies that have considered margin
positivity to be a well-established feature of a more aggres-
sive prostate cancer disease course after prostatectomy
[17,18].
Bisulfite Treatment
Using the EZ DNA Methylation Kit™ (Zymed Research,
Orange, CA) protocol, 2 μg of genomic DNA from each
patient sample was treated with denaturation buffer,
sodium bisulfite (converting unmethylated cytosine resi-
dues to uracil), and desulphonation buffer, with elution
of the bisulfite-modified DNA into 10 μl of buffer.
TGFBI Regulatory Region Template Enrichment
To amplify the regulatory region (promoter region and
first exon) of the TGFBI gene in each patient sample, 2 μL
of the bisulfite-modified DNA was used as a template in a
polymerase chain reaction (PCR) using the FailSafe™ PCR
System with 2× PreMix J buffer (Epicentre Biotechnolo-
gies, Madison, WI). Primer set "M1/M2" was used in this
PCR amplification. Primers M1 and M2 were designed to
flank the TGFBI regulatory region without any potential
methylation sites, thus allowing for amplification of both
methylated and unmethylated DNA (i.e., primers M1 and
M2 were "unbiased" vis-à-vis methylation status) (Fig. 1).
The PCR conditions were as follows: a hot start at 95°C
for 5 minutes (to fully denature the bisulfite-modified
genomic DNA), 35 amplification cycles (94°C for 30 sec-
onds for denaturation, 53°C for 30 seconds for primer
annealing, and 72°C for 60 seconds for extension), and a
final full extension at 72°C for 5 minutes. A MSP method
using a methylation-specific primer set was then devel-
oped and executed using the TGFBI  regulatory region
product from the M1/M2 PCR amplification as the tem-
plate for MSP, as described in the Results section.
Of note, successful template enrichment of the TGFBI reg-
ulatory region was demonstrated by the use of a nested
"M3/M4" primer set to perform a PCR amplification on 1
μl of 1:100 diluted product from the first PCR amplifica-
tion using primers M1 and M2. Primers M3 and M4 were
designed to flank the TGFBI regulatory region, with the
M3/M4 product sequence flanked by primers M1 and M2
(Fig. 1). Like primers M1/M2, M3/M4 were "unbiased"
primers that bound to DNA lacking potential methylation
sites so that both methylated and unmethylated DNA
would be amplified. The PCR conditions for the M3/M4
reaction were the same as for the M1/M2 reaction except
for use of 2× PreMix D buffer, a hot start at 94°C for 2
Predicted CpG island and methylated CpG sites profile of the TGFBI regulatory region in human tumor cell lines [16] Figure 1
Predicted CpG island and methylated CpG sites profile of theTGFBI regulatory region in human tumor cell 
lines16[16]. Locations of unmethylated PCR primers (M1-M4, U1-U2) and methylation-specific primers (P1-P6) are marked as 
"-".BMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
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minutes, and 54°C as the primer annealing temperature.
The intended amplification of the TGFBI  regulatory
region was proven by the presence of a 629-bp band using
this M3/M4 primer pair. Thus, the PCR reaction using the
M3/M4 primer pair served as a template control to ensure
the successful and sequence-specific amplification of the
TGFBI  promoter, thereby mitigating the possibility of
false-negative results with the MSP method. The template
enrichment primer pairs were: M1:5'AGTTGGGGAGGGT
GGTTAGTT3' (-548 to -529), and M2: 5'ACCCCAAC-
TACCT AACCTTCC3' (+162 to +184), M1/M2 PCR prod-
uct of 732 bp; M3: 5'TTTGTAGTGTTT TGTAGTTTTAAGA
TT3' (-457 to -430), and M4: 5'TAACCTTCCACAAC-
CCCTAACCA A3' (+172 to +148), M3/M4 PCR product of
629 bp.
Reverse Transcription and Quantitative PCR
The expression of the TGFBI gene was analyzed by quan-
titative real-time reverse transcription-PCR as described
previously [16]. The first strand of cDNA was synthesized
from 2 μg of total RNA using Superscript III reverse tran-
scriptase (Invitrogen, Carlsbad, CA). Both human TGFBI
and GAPDH RT-PCR primer sets were obtained from
SuperArray Bioscience (Frederick, MD).
Western and Northern Blotting
For analysis of TGFBI protein level, conditioned medium
was collected and the protein in the medium was concen-
trated by adding SP sepharose at the proportion of 25 μl/
ml medium (Amersham, Arlington Heights, IL) and
eluted with 1× SDS loading buffer. Whole cell lyses were
also collected and their protein concentrations were used
to normalize the loading of medium samples. After sepa-
ration and transferring to the membrane, medium sam-
ples were immunoblotted with Rabbit anti-human TGFBI
polyclonal antibody (1:1,000 dilution) (R&D System,
Minneapolis, MN), and the whole cell lysis samples were
immunoblotted with β-actin antibody as control.
Total RNA was prepared with TRIzol reagent (Gibco,
Carlsbad, CA) according to the manufacturer's instruc-
tions. For Northern blotting, 20 μg of total RNA was dena-
tured and separated on a 1% denaturing agarose
formaldehyde gel, transferred to a nylon membrane (Mil-
lipore, Bedford, MA) by downward capillary blotting in
20× SSC followed by UV crosslinking. TGFBI and GAPDH
cDNA probes were labeled with [α-32P]dCTP with a ran-
dom primed DNA labeling kit (Boehringer Mannheim,
Mannheim, Germany). GAPDH expression level was used
as control.
Statistical Analysis
Frequencies of TGFBI promoter hypermethylation accord-
ing to clinicopathological parameters in lung tumors,
including the parameter of metastatic vs. primary lung
cancer specimen, were compared using the χ2 test. P <
0.05 was considered to be statistically significant. Methyl-
ation status of the TGFBI promoter in prostate cancer sam-
ples was correlated with the presence vs. absence of one or
more classic pathological feature(s) of locoregional tumor
invasiveness in the patients' corresponding prostatectomy
specimens. Statistical comparison of locoregional inva-
siveness profile status (absent vs. present) according to the
TGFBI promoter methylation status was performed using
the χ2 test.
Results
Design of Methylation-Specific Primers for the MSP 
Method
A 620-bp length of a CpG island, spanning the proximal
promoter and the first exon of the TGFBI gene, was iden-
tified by screening the entire TGFBI  genomic sequence
using CpG plot prediction analysis http://www.ebi.ac.uk/
emboss/cpgplot. Our previous work had defined the
methylation status of a total of 49 CpG sites across 0.6 kb
of the TGFBI promoter in human tumor cell lines, and we
had demonstrated a dense methylation pattern in lung,
kidney, and DU145 prostate tumor cell lines [16]. Based
on these data, in the present study we designed three pairs
of methylation-specific PCR primers ("P1-P6," Fig. 1 and
Table 1). Nucleotide positions were numbered relative to
the translation start site (TSS) (+1). Each primer was
designed to bind to a different stretch of the TGFBI pro-
moter with each of these distinct stretches containing 2–3
possible methylated sites (boldface in Table 1). The nucle-
otide C in non-CpG sites and unmethylated CpG sites
Table 1: Primer sequences and optimized annealing temperatures for each pair of primers
Primers Sequence CpG sites Location Length (bp) Annealing temp. (°C)
P1 5' TATGTAGGATCGAAGTTTTC 3' 2 -405 ~ -64 341 60–62
P2 5' TAAAAACGCCTCCGCCG 3' 3
P3 5' GGGTATAGTGCGGGAGC 3' 2 -235 ~ +22 257 65–67
P4 5' CAACCGCACGAAAAACGC 3' 3
P5 5' GAGGCGTTAGGCGGTTC 3' 3 -180 ~ -26 155 64.5
P6 5' AACTAACGACCGACGAAC 3' 3
U1 5' GAGGTGTTAGGTGGTTTGTT 3' 3 -180 ~ +71 252 62
U2 5' CCCACCAAAATCACAACAA 3' 3BMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
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would be modified to T (sense strand) or A (antisense
strand) by bisulfite treatment, whereas C would remain as
C in methylated CpG sites. Thus, for example, PCR ampli-
fication with primer set P1-P2 on a particular sample
would yield a PCR product only if the TGFBI region in this
sample was actually methylated at the two CpG sites
encompassed by primer P1 and the three CpG sites
encompassed by primer P2. As a control, primers U1/U2
were designed to amplify unmethylated DNA, in which
case the nucleotide C in CpG sites would be modified to
T or A by bisulfite treatment.
Validation of Methylation-Specific Primers by MSP
To ensure the accurate and efficient amplification of
methylated TGFBI DNA by the methylation-specific prim-
ers, we optimized the annealing temperature for these
primers using 293T and H522 tumor cells as positive con-
trols, and normal human bronchial epithelial (NHBE)
cells and human mammary epithelial cells (HMEC) as
negative controls. Our previous bisulfite sequencing stud-
ies demonstrated that 293T and H522 are densely methyl-
ated at the TGFBI promoter region, whereas NHBE and
HMEC cells are unmethylated [16]. MSP was performed
in a final reaction volume of 25 μl, including 1 μl of
diluted PCR products (1:200) from the M1/M2 amplifica-
tion as the template and 1.25 pmol of primer sets (P1/P2,
P3/P4, or P5/P6). The FailSafe™ PCR System (with 2×
PreMix D buffer) was used for all of the PCRs, and the PCR
conditions were as follows: a hot start at 94°C for 2 min-
utes followed by 35 cycles of PCR (94°C for 30 seconds,
annealing for 30 seconds, and 72°C for 30 seconds), and
a final extension at 72°C for 5 minutes. All the PCR prod-
ucts were analyzed by 2% agarose gel electrophoresis and
the fragments were visualized by ethidium bromide stain-
ing. The optimized annealing temperature for each primer
set and the lengths of PCR products are shown in Table 1.
Dense methylation of the TGFBI promoter was observed
in 293T and H522 cells but not in NHBE and HMEC cells
(Fig. 2). Primer set U1/U2 was used to amplify unmethyl-
ated DNA, and thus no PCR products were obtained for
293T and H522 cells but PCR products were observed for
NHBE and HMEC cells.
MSP-Based Methylation Screening of the TGFBI 
Promoter in Lung Tumor Samples
Fifty lung cancer patient samples were screened for TGFBI
methylation by MSP. 293T and HMEC cell lines were used
as positive and negative controls, respectively. As shown
in Figure 3A, 22 of 50 (44.0%) samples were identified as
harboring methylated sites at different levels in the TGFBI
promoter. Methylation frequencies detected by primer
sets P1/P2, P3/P4, and P5/P6 were 20/50 (40.0%), 17/50
(34.0%), and 8/50 (16.0%), respectively. Since all sam-
ples harboring TGFBI methylation at the P5/P6 loci also
had methylation at the P1/P2 and P3/P4 loci, methylation
detected by the P5/P6 primer set indicated that at least 16
CpG sites were methylated in the TGFBI promoter due to
the fact that the P1-P6 primers bound to locations con-
taining a total of 16 potential methylated CpG sites (Table
1).
MSP-Based Methylation Screening of the TGFBI 
Promoter in Prostate Tumor Samples
Fifty prostate cancer patient samples were screened for
TGFBI methylation by MSP. H522 and HMEC cell lines
were used as positive and negative controls, respectively.
As shown in Figure 3B, 41 of 50 (82.0%) samples were
identified as harboring methylated sites at different levels
in the TGFBI promoter. Methylation frequencies detected
by primer sets P1/P2, P3/P4, and P5/P6 were 40/50
(80.0%), 27/50 (54.0%), and 14/50 (28.0%), respec-
tively. Consistent with the findings in lung cancer, 100%
(14/14) of prostate cancer samples with methylated CpG
sites detected by P5/P6 also had CpG methylation at both
P1/P2 and P3/P4 regions.
Validation of methylation-specific primers using 293T and  H522 as positive controls and NHBE and HMEC as negative  controls Figure 2
Validation of methylation-specific primers using 
293T and H522 as positive controls and NHBE and 
HMEC as negative controls. U1/U2 is used for amplifica-
tion of unmethylated DNA. M3/M4 is used as a TGFBI tem-
plate control for enrichment of both methylated and 
unmethylated DNA templates.BMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
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Methylation status of the TGFBI promoter in lung cancer tissue samples (A) and prostate cancer tissue samples (B) using the  MSP method Figure 3
Methylation status of the TGFBI promoter in lung cancer tissue samples (A) and prostate cancer tissue sam-
ples (B) using the MSP method. "M": DNA 2-log marker; "+": positive methylated control; "-": negative unmethylated con-
trol. Numbers 1–50 correspond to each of the 50 lung and prostate cancer patients and their respective specimens.BMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
Page 7 of 11
(page number not for citation purposes)
Correlation of TGFBI Methylation Status with 
Clinicopathological Features
To determine whether the TGFBI methylation status of the
lung cancer samples was correlated with clinicopatholog-
ical features of lung cancer patients, univariate analyses
were carried out to correlate the methylation status of the
TGFBI promoter with various clinicopathological param-
eters. Only dense methylation of the TGFBI  promoter
(i.e., 16 methylated CpG sites detected) was found to cor-
relate with metastatic phenotype, with a significantly
higher frequency of dense methylation in metastatic
tumor samples (6/14, 42.9%) than in primary tumor sam-
ples (2/36, 5.6%) (p < 0.05) (Tables 2, 3). These results
suggest a positive correlation between dense methylation
of the TGFBI promoter and metastasis in human lung can-
cer.
Likewise, the TGFBI methylation status of prostate cancer
specimens was correlated with pathological features of the
patients' prostatectomy specimens including those of
locoregional invasiveness (i.e., extracapsular extension of
tumor, seminal vesicle involvement by tumor, margin
positivity with tumor, and/or regional lymph node tumor
involvement) (Table 4). Similar to the findings for lung
cancer samples, a significantly higher frequency of dense
methylation was identified in prostate cancer specimens
with the characteristic of locoregional invasiveness. Dense
methylation of the TGFBI promoter was present in 38.9%
(7/18) of prostate cancer samples with locoregional inva-
siveness vs. only 19.4% (6/31) of prostate cancer samples
without locoregional invasiveness (Table 5, p  < 0.05).
These results suggest a positive correlation between dense
methylation of the TGFBI  promoter and locoregional
invasiveness in human prostate cancer.
In summary, dense methylation of the TGFBI promoter
was associated with invasiveness in prostate cancer and
metastasis in lung cancer.
Reduced TGFBI Expression in Lung and Prostate Cancer 
Cell Lines is Mainly due to Promoter Hypermethylation
Direct bisulfite sequencing revealed that the TGFBI gene
promoter is hypermethylated in some human lung and
prostate tumor cell lines (H522, H810, H1417, DU145),
but unmethylated or sparsely methylated in A549, PC3,
and BEP2D (papillomavirus-immortalized human bron-
chial epithelial cells) cell lines [16]. In this study, methyl-
ation status detected by the MSP method using primer
pair P5/P6 was further validated in these cell lines. As
expected, PCR bands were obtained for the tumor cell
lines with TGFBI  hypermethylation (H522, H810,
H1417, DU145), but not for A549, PC3, and BEP2D cell
lines (Fig. 4A). After treatment with TGF-β1 at 5 ng/ml for
6 h, induction of TGFBI mRNA level was not detectable in
tumor cell lines with TGFBI hypermethylation, whereas
A549, PC3, and BEP2D showed a high level of induction
(Fig. 4B). Furthermore, treatment with a demethylating
agent (Aza-CdR) at 10 μM for 4 days resulted in a substan-
tially increased level of both TGFBI mRNA and protein in
H522, H810, H1417, and DU145 cells, but not in A549
and PC3 cells (Fig. 4C &4D).
Discussion
Metastasis is the major cause of death for both lung and
prostate cancer patients [1-4]. Therefore, identification of
biomarkers of invasiveness and metastasis would help to
identify those patients who are more likely to have tumor
dissemination, progression, or recurrence. We have
shown previously that CpG islands of the TGFBI gene pro-
moter are hypermethylated in human tumor cell lines
[16]. However, the method used in our previous study
was DNA sequencing of bisulfite-treated samples, which
is labor-intensive and unsuitable for the rapid screening
of methylation status of the TGFBI promoter in a large
number of clinical patient samples.
Therefore, the present study was focused on optimizing
and implementing a MSP method for accurate and effi-
cient screening of TGFBI promoter methylation. For this
Table 2: Univariate analyses of TGFBI methylation in non-small 
cell lung cancer patients
Variable Methylation status P-value
Absent Present
Age (mean ± SD) 57.5 ± 8.4 60.0 ± 8.2 0.3037
Sex 0.4900
Male 26 (56.5%) 20 (43.5%)
Female 1 (25.0%) 3 (75.0%)
Pathological stage 0.8766
I 9 (50.0%) 9 (50.0%)
II 6 (50.0%) 6 (50.0%)
III 10 (62.5%) 6 (37.5%)
IV 2 (50.0%) 2 (50.0%)
Differentiation 0.3890
Well 1 (50.0%) 1 (50.0%)
Moderate 15 (48.4%) 16 (51.6%)
Poor 8 (57.1%) 6 (42.9%)
Unknown 3 (100.0%) 0 (0.0%)
Tumor size (cm) (mean ± SD) 4.19 ± 2.34 4.62 ± 2.62 0.6543
Tumor status 0.2946
T1 11 (61.1%) 7 (38.9%)
T2 12 (46.2%) 14 (53.8%)
T3 2 (66.7%) 1 (33.3%)
T4 1 (100.0%) 0 (0.0%)
Tx 2 (100.0%) 0 (0.0%)
Metastatic status 0.6871
Primary tumor 22 (61.1%) 14 (38.9%)
Lymph node metastasis 4 (40.0%) 6 (60.0%)
Distant metastasis 2 (50.0%) 2 (50.0%)
Histology 0.6614
Adenocarcinoma 14 (58.3%) 10 (41.7%)
Squamous cell carcinoma 12 (52.2%) 11 (47.8%)BMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
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purpose, we designed three pairs of methylation-specific
primers based on the methylation profiles of the TGFBI
promoter reported in human tumor cell lines [16]. MSP
conditions were optimized and successfully used for
examining the methylation status of the TGFBI promoter
in 50 cases each of lung tumors and prostatectomy speci-
mens of prostate adenocarcinoma patients. Overall,
TGFBI methylation was present in 44.0% (22/50) of lung
cancer specimens and 82.0% (41/50) of prostate cancer
specimens. Interestingly, dense methylation (≥ 16 methyl-
ated CpG sites) of the TGFBI promoter was identified in
16.0% (8/50) of lung cancer and 28.0% (14/50) of pros-
tate cancer specimens, respectively, which in turn corre-
lated significantly with metastatic phenotype in lung
cancers and locoregional invasiveness in prostate cancers.
Therefore, cancer cells with a densely methylated TGFBI
promoter may be prone to invasiveness in prostate cancer
and metastasis in lung cancer.
It should be noted that the exact percent tumor involve-
ment in the slices of prostate tissue used for DNA extrac-
tion was not quantified. Thus, the percentage of tumor
cells in tumor specimens or proportion of tumor cells
with TGFBI promoter methylation may be very low in
some tumor samples. In the present study, we used the
product from the first round of PCR (M1/M2) as template
to perform the second round of MSP analysis in order to
increase the amplification efficiency and avoid false-nega-
tive results.
Cell-cell adhesion and cell-substrate adhesion are critical
to the preservation of normal tissue architecture, and dis-
ruption of the cell adhesion system can lead to tumor
infiltration and metastasis [19]. The TGFBI protein is
composed of 683 amino acids containing four homolo-
gous internal repeat domains and has been reported to
function as an extracellular matrix protein that mediates
cell adhesion and migration through interactions with
integrin receptors α3β1, αvβ3, and αvβ5 [20-22]. TGFBI
protein is a component of extracellular matrix (ECM) in
lung, bladder, and skin [23], and it promotes adhesion
and spreading of dermal fibroblasts and corneal epithelial
cells in vitro. Thus, silencing of the TGFBI promoter by
hypermethylation would result in a deficiency of the gene
product, which in turn may lead to the disruption of cell-
ECM interaction and contribute to invasion and metasta-
sis of cancer cells. Our previous work identified a dense
TGFBI  methylation pattern in lung tumor cell lines
(H522, H810, and H1417) and a metastasized prostate
tumor cell line (DU145) [16]. Our present results showed
that 16.0% of lung cancer and 28.0% of prostate cancer
samples had dense TGFBI  promoter hypermethylation
and that such dense methylation was associated with
metastasis in lung cancer and invasiveness in prostate can-
cer, suggesting a potential prognostic value of TGFBI
hypermethylation in lung and prostate cancer patients.
The TGF-β signaling pathway plays an important role in
regulating proliferation and differentiation in normal
lung and prostate epithelium [24,25]. Previous reports
have shown that both lung and prostate cancer cells
become resistant to the antiproliferative effects of TGF-β
during cancer formation [26,27]. TGFBI, as one of the
downstream effectors of the TGF-β signaling pathway, has
been shown to be expressed ubiquitously in a variety of
normal human tissues but is downregulated or inacti-
Table 3: Methylation status of the TGFBI promoter in primary and metastatic (lymph node and remote) lung cancer specimens
Source of lung cancer specimen Number of methylated CpG sites
05 – 1 0 1 6
Primary site (n = 36) 22 (61.1%) 12 (33.3%) 2 (5.6%)*
Lymph node (n = 10) 4 (40.0%) 2 (20.0%) 4 (40.0%)*
Remote metastasis (n = 4) 2 (50.0%) 0 (0.0%) 2 (50.0%)*
* P < 0.05
Table 4: Univariate analyses of TGFBI methylation in prostate 
cancer patients
Variable Methylation status P-value
Absent Present
Gleason score 0.6241
6 2 (16.7%) 10 (83.3%)
7 (3+4) 6 (25.0%) 18 (75.0%)
7 (4+3) 1 (8.3%) 11 (91.7%)
9 0 (0.0%) 1 (100.0%)
Extracapsular extension 0.8840
Negative 8 (20.0%) 32 (80.0%)
Positive 1 (11.1%) 8 (88.9%)
Seminal vesicle involvement 0.5582
Negative 7 (16.7%) 35 (83.3%)
Positive 1 (16.7%) 5 (83.3%)
Prostatectomy margin positivity 0.4364
Negative 8 (23.5%) 26 (76.5%)
Positive 1 (6.7%) 14 (93.3%)
Regional lymph node involvement 0.3975
Negative 7 (18.4%) 31 (81.6%)
Positive 0 (0.0%) 1 (100.0%)BMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
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vated in many human tumor cell lines including lung and
prostate tumor cell lines [15]. Thus, blockage or inactiva-
tion of the TGF-β pathway caused by loss of TGF-β recep-
tors (I, II, III) and mutations of Smads (2, 3, 4) would lead
to a lack of response to TGF-β, and subsequent downreg-
ulation of TGFBI expression. Our previous work showed
that most CpG sites of the TGFBI promoter were unmeth-
ylated in normal NHBE (normal human bronchial epithe-
lial) cells and PHEC (prostate human epithelial cells) that
expressed a high level of TGFBI mRNA. In contrast, three
lung tumor cell lines (H522, H810, and H1417) and one
prostate tumor cell line (DU145) that expressed an unde-
tectable or a much lower level of TGFBI mRNA showed
hypermethylation in the TGFBI promoter [16]. Consistent
with this report, in the present study MSP-based PCR
products were identified in H522, H810, H1417, and
DU145 tumor cells but not in A549 and PC3 cells, sug-
gesting that the MSP method can accurately and efficiently
screen the methylation status of the TGFBI promoter. In
addition, dense methylation of the TGFBI  promoter is
responsible for gene silencing since induction of TGFBI
expression by TGF-β1 was totally lost in the tumor cells
Table 5: Methylation status of the TGFBI promoter in prostate cancer prostatectomy specimens with or without locoregional 
invasiveness
Locoregional invasiveness status of prostatectomy specimen Number of methylated CpG sites
0 5–10 16
Positive (n = 18) 2 (11.1%) 9 (50.0%) 7 (38.9%)*
Negative (n = 31) 7 (22.6%) 18 (58.1%) 6 (19.4%)*
*P < 0.05
(A) Methylation status of the TGFBI promoter in lung and prostate tumor cell lines using the P5/P6 primer pair in MSP Figure 4
(A) Methylation status of the TGFBI promoter in lung and prostate tumor cell lines using the P5/P6 primer pair 
in MSP. (B) Induction of TGFBI expression in lung and prostate tumor cell lines by TGF-β1 determined by Northern blotting. 
Cells were treated with TGF-β1 at 5 ng/ml for 6 hours. Total RNAs were isolated and used for determining the mRNA level of 
the TGFBI gene before and after treatment. (C) TGFBI mRNA level in lung and prostate tumor cell lines with or without 
demethylating treatment determined by real-time RT-PCR. Cells were treated with Aza-CdR at 10 μM for 4 days with medium 
changed each day. Relative quantification of the TGFBI expression was performed by using real-time PCR, calibrated and nor-
malized to its expression in DU145 cells. (D) TGFBI protein level in lung and prostate tumor cell lines with or without demeth-
ylating treatment examined by Western blotting.BMC Cancer 2008, 8:284 http://www.biomedcentral.com/1471-2407/8/284
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with  TGFBI  hypermethylation, whereas demethylating
treatment with Aza-CdR resulted in the re-expression of
TGFBI in these tumor cell lines. In summary, dense meth-
ylation of the TGFBI promoter correlates with gene silenc-
ing that in turn may promote an advanced tumorigenic
phenotype, such as invasiveness in prostate cancer and
metastasis in lung cancer.
There is one report in the literature showing that overex-
pression of TGFBI promotes metastasis of SW480 colon
cancer cells by enhancing extravasation [28]. However, a
significant downregulation of TGFBI expression has been
demonstrated in HT29 colon cancer cells [15] and in dif-
ferent types of primary human cancers [15,29-32], which
is further substantiated by the present data demonstrating
a correlation between promoter hypermethylation and
TGFBI silencing in human lung and prostate cancer cells.
It is highly possible that dysregulation of TGFBI expres-
sion is tumor cell or type-specific; moreover, TGFBI may
be a double-edged sword whose loss or gain of expression
may help promote tumorigenesis. Future studies will be
required to clarify the functional complexity of TGFBI in
human tumor progression.
Conclusion
We designed methylation-specific primers and optimized
MSP conditions to examine the methylation status of the
TGFBI promoter in a large number of human lung and
prostate cancer specimens. Our current method demon-
strated that the TGFBI promoter was densely methylated
(at least 16 methylated CpG sites) in 16.0% of lung cancer
specimens and 28.0% of prostate cancer specimens, and
such dense methylation correlated with metastatic pheno-
type in lung cancer and invasiveness in prostate cancer. In
addition, TGFBI promoter hypermethylation was associ-
ated with gene silencing in human lung and prostate
tumor cell lines. Thus, TGFBI promoter hypermethylation
may represent a valuable prognostic biomarker in both
lung and prostate cancer patients.
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